Merit Medical Systems Inc (MMSI)
Healthcare
Medical Instruments & Supplies
85.00 $
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Merit Medical Systems Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
5.0$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
60Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
97.5%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
0.5
Performance
Perf. 1M
Price performance over the last month.
9.90%
Perf. 3M
Price performance over the last 3 months.
2.00%
Perf. 6M
Price performance over the last 6 months.
-19.80%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
-23.70%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-26.8%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
37.1
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
18.1
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
1.5
P/B
Price-to-book ratio: market value relative to book equity.
3.2
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
3.2
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
13.1
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
24.4
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
48.7%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
11.5%
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
9.0%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
9.1%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
4.7%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
59.8%
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
0.5
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
8.51
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
7 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
7.50%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
38.80%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
11.66%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
6.06%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
8.00%
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
4
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
19
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
74
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
7 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
B (60 out of 100)
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
8.51
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.46 | -2.60 | 355 | 9.90 | 7.90 | 69 | 65 |
| 2025: Q1 | 0.49 | 2.00 | 354 | 9.50 | 8.50 | 41 | 19 |
| 2025: Q2 | 0.54 | -11.60 | 382 | 13.00 | 8.50 | 83 | 105 |
| 2025: Q3 | 0.46 | -3.00 | 384 | 13.10 | 7.20 | 75 | 52 |
| 2025: Q4 | 0.63 | 37.30 | 394 | 11.00 | 9.60 | 99 | 77 |
| 2026: Q1 | 0.68 | 38.90 | 382 | 7.90 | 10.70 | 41 | 25 |
| 2026: Q2 | 0.65 | 20.40 | 419 | 9.60 | 9.30 | 69 | 52 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Merit Medical Systems, Inc. entwirft, entwickelt, fertigt und vermarktet Einweg-Medizinprodukte für interventionelle, diagnostische und therapeutische Verfahren in den USA, China, Japan, Deutschland, Frankreich, dem Vereinigten Königreich und international.
| Employees | 7,500 |
|---|---|
| Headquarters | South Jordan, UT |
| Website | merit.com |
| IPO Date | 9. Aug 1990 |
| Next Earnings | 29. Jul 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Martha Goldberg Aronson | President, CEO & Director | 1967 |
| Raul Parra Jr., CPA | CFO & Treasurer | 1979 |
| Neil W. Peterson | Chief Operating Officer | 1967 |
| Brian G. Lloyd J.D. | Chief Legal Officer & Corporate Secretary | 1961 |
| Michel J. Voigt | Chief Human Resources Officer | 1973 |
| Jason Treft | Chief Information Officer | – |
| Sarah Comstock | Vice President of Global Communications | – |
| John Knorpp | Chief Regulatory Affairs Officer | – |
| Ricardo Alvarez | Managing Director of Operation Merit Medical Tijuana | – |
| Mark Butler | Executive Vice President of Merit Medical EMEA | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.